The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
45 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $23,703,728 in first-year total cost, median $342,592.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-H (11)]20
- Special Emphasis Panel[ZRG1 ETTN-P (13)]9
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]8
- Special Emphasis Panel[ZRG1 ETTN-C (10)]3
- Special Emphasis Panel[ZRG1 RPHB-Y (13)]3
Most frequent institutions
- OLEOLIVE, INC.2
- OLIGOMERIX, INC2
- PRONEUROGEN, INC.2
- VIVREON BIOSCIENCES, LLC2
- 712 NORTH, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Open-label extension of a 3-month blinded clinical trial of PTI-1251R44AG065152-01 | BURNS, LINDSAY H | CASSAVA SCIENCES, INC, TX | $2,499,896 | ZRG1 |
| 2019 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease2R44AG055205-04 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $1,250,000 | ZRG1 |
| 2019 | Device to control circadian-effective light in Alzheimer's disease environments2R44AG060857-02 | PAGE, ERIK | ERIK PAGE AND ASSOCIATES, INC., CA | $1,240,470 | ZRG1 |
| 2019 | GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD1R44AG066384-01 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $1,228,934 | ZRG1 |
| 2019 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease2R44AG043243-03 | NASH, KEVIN RONRAVULA, SATHEESH B | EPIGEN BIOSCIENCES, INC., CA | $1,169,102 | ZRG1 |
| 2019 | Rapid Profiling of the Plasma Proteome and Machine Learning Analytics for Non-Invasive Diagnosis of Alzheimer's Disease1R44AG065051-01 | MANNING, WILLIAM CLARENCE | SEER, INC., CA | $1,130,758 | ZRG1 |
| 2019 | Structurally Diverse GABA-A ÃÂÃÂÃÂÃÂÃÂÃÂÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD1R44AG063607-01 | ROSENZWEIG-LIPSON, SHARON | AGENEBIO, INC., MD | $1,118,843 | ZRG1 |
| 2019 | Ubiquitin Proteasome System and Molecular Signatures of Alzheimer’s Disease2R44AG057231-02 | BUTT, TAUSEEF R. | LIFESENSORS, INC., PA | $1,012,084 | ZRG1 |
| 2019 | Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine1R44AG066366-01 | SUN, MIAO-KUN | SYNAPTOGENIX, INC., NY | $986,918 | ZRG1 |
| 2019 | CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease1R44AG060826-01A1 | JOHANSSON, JAN | ARTERY THERAPEUTICS, INC., CA | $479,682 | ZRG1 |
| 2019 | Development of Serious Games and Physical Activities Instructed by a Social Robot for Improving the Well-being of Elderly Individuals with Alzheimer's Disease and Dementia1R44AG066439-01 | MAHOOR, MOHAMMAD | DREAM FACE TECHNOLOGIES, LLC, CO | $463,523 | ZRG1 |
| 2019 | Novel formulations of Allopregnanolone to treat Alzheimer's Disease1R43AG063674-01A1 | BRINTON, ROBERTA EILEENCROCKETT, TAMARAOSSANNA, NINA | PRONEUROGEN, INC., AZ | $449,886 | ZRG1 |
| 2019 | Whole Blood Filter Paper Assay for Alzheimers Disease1R43AG065039-01 | SELIGMANN, BRUCE E. | BIOSPYDER TECHNOLOGIES, INC., CA | $436,986 | ZRG1 |
| 2019 | Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease1R43AG065069-01 | CARDELLI, JAMES | OLEOLIVE, INC., LA | $346,991 | ZRG1 |
| 2019 | Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease1R44AG063691-01 | MAHLEY, ROBERT W.TONG, LESLIE | GABAERON, INC., CA | $342,592 | ZRG1 |
| 2019 | A Novel Biological marker and ELISA Assay for Determination of Cognitive Resilience in Alzheimer's Disease1R43AG064998-01 | XU, DESHENG | COGNEXT DIAGNOSTICS, LLC, MD | $337,540 | ZRG1 |
| 2019 | Advance Care Planning in the Dementias: Culturally-Tailored Caregiver Education for African Americans1R44AG065095-01 | BONNER, GLORIA JCOLLINGE, WILLIAM B. | COLLINGE AND ASSOCIATES, OR | $331,097 | ZRG1 |
| 2019 | Improving Mobile Access for Recruiting Study Volunteers from Underrepresented Populations for Alzheimer's Disease Research and Other Studies1R43AG055218-01A1 | AGGARWAL, RAJNEESHLANGBAUM, JESSICA BROOKE | PROVOC, INC., DC | $327,980 | ZRG1 |
| 2019 | Development of Neurocognitive Eye Tracking for Rapid Screening of Mild Cognitive Impairment1R43AG066427-01 | ETTENHOFER, MARKLISTON, DORION BRYCE | NEUROFIT, INC., CA | $305,604 | ZRG1 |
| 2019 | Digital multidomain lifestyle intervention to address cognitive health and modifiable risk factors for Alzheimer's disease1R44AG063672-01 | BOTT, NICHOLAS | NEUROTRACK TECHNOLOGIES, INC., CA | $298,097 | ZRG1 |
| 2019 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease1R43AG061995-01A1 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $270,902 | ZRG1 |
| 2019 | CareBand: Wearable Technology for People with Dementia1R43AG063685-01 | RUSSEK-SOBOL, ADAM | CAREBAND, INC., OH | $228,778 | ZRG1 |
| 2019 | Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies1R43AG065066-01 | SUCKOW, ARTHUR THOMAS | DTX PHARMA, LLC, CA | $225,073 | ZRG1 |
| 2019 | Cycli: A Guided Exercise System for Reducing Comorbidities in Individuals with Alzheimer's Disease1R43AG063651-01 | ZONDERVAN, DANIEL | FLINT REHABILITATION DEVICES, CA | $225,000 | ZRG1 |
| 2019 | An acoustofluidic device for diagnosing preclinical Alzheimer's disease1R43AG063643-01 | WANG, LIN | ASCENT BIO-NANO TECHNOLOGIES, INC., NC | $225,000 | ZRG1 |
| 2019 | Discovery and validation of OMA1 inhibitors1R43AG063642-01 | ALAVI, MARCEL V | 712 NORTH, INC., CA | $224,960 | ZRG1 |
| 2019 | Non-invasive efficient brain delivery of Prussian Blue for treatment of Alzheimer disease1R44AG066386-01 | WEINBERG, IRVING | WEINBERG MEDICAL PHYSICS, LLC, MD | $224,888 | ZRG1 |
| 2019 | ALZ-Stage: Artificial intelligence driven technology with adaptive suite of personalized tests to detect and determine progressive stage of Alzheimers disease1R43AG063581-01A1 | SCHAFF, JENNIFER | ELDER RESEARCH, INC., VA | $224,850 | ZRG1 |
| 2019 | Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)1R43AG063652-01 | CROCKETT, TAMARAHAY, MEREDITHOSSANNA, NINA | PRONEUROGEN, INC., AZ | $222,855 | ZRG1 |
| 2019 | Development of non-invasive research and diagnostics platform for Alzheimer's disease based on plasma exosomes1R43AG063589-01 | ILIUK, ANTON | TYMORA ANALYTICAL OPERATIONS, LLC, IN | $215,369 | ZRG1 |
| 2019 | Presymptomatic Diagnostic Tools for Alzheimers Disease by Blood Neuron Derived Exosome Analysis1R43AG065072-01 | EITAN, EREZ | NEURODEX INC, MA | $212,300 | ZRG1 |
| 2019 | Telerehabilitation Combining Virtual Reality Adaptable Games and Drug Therapy for Early Alzheimer's Disease1R43AG065035-01 | BURDEA, GRIGORE C | BRIGHT CLOUD INTERNATIONAL CORPORATION, FL | $181,409 | ZRG1 |
| 2019 | EEG-Based Assessment of the Cognitive Impairment of Alzheimer's Disease1R43AG065058-01 | KOFFLER, RICHARD | GREENWINGS BIOMEDICAL, INC., CA | $175,210 | ZRG1 |
| 2019 | Predicting Impending Cognitive Decline in Cognitively Normal Individuals1R44AG065126-01 | SHANKLE, WILLIAM RODMAN | MEDICAL CARE CORPORATION, CA | $129,734 | ZRG1 |
| 2019 | Development and validation of novel tests in the DCT drawing analysis platform for the detection of Alzheimer’s Disease-related early cognitive impairment1R43AG066291-01 | SOUILLARD-MANDAR, WILLIAM | DIGITAL COGNITION TECHNOLOGIES, INC., MA | $129,173 | ZRG1 |
| 2018 | Small molecule therapeutics for Alzheimer's Disease2R44AG055182-02 | DEWJI, NAZNEEN N | CENNA BIOSCIENCES, INC., CA | $999,998 | ZRG1 |
| 2018 | Virtual Patient Behavioral Response Training for Family Caregivers2R44AG057272-02 | KAJIYAMA, BRUNO | PHOTOZIG, INC., CA | $732,556 | ZRG1 |
| 2018 | Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD1R44AG062021-01 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $499,433 | ZRG1 |
| 2018 | EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY1R43AG059520-01A1 | BENJAMIN, CYNTHIA LOUISE | TOGETHER SENIOR HEALTH, INC., CA | $494,106 | ZRG1 |
| 2018 | Computerized tests of cognitive decline in presymptomatic Alzheimer’s disease1R44AG062076-01 | PEBLER, PETERWOODS, DAVID L | NEUROBEHAVIORAL SYSTEMS, INC., CA | $430,140 | ZRG1 |
| 2018 | Smartphone phenotype collection for diagnostic screening of mild cognitive impairment1R43AG062072-01 | ARMENTROUT, STEVEN L | PARABON NANOLABS, INC., VA | $394,297 | ZRG1 |
| 2018 | Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways1R44AG062129-01 | IZZO, NICHOLAS JOHN | COGNITION THERAPEUTICS, INC., PA | $360,119 | ZRG1 |
| 2018 | The Development of a High Throughput Whole Brain Alzheimer's Disease Drug Screening Pipeline1R44AG062017-01 | BLECKERT, ADAM A | TISSUEVISION, INC., MA | $349,883 | ZRG1 |
| 2018 | The Alzheimer's Therapeutics Screening Assay: a high-throughput drug-discovery platform utilizing neurons and microglia derived from human induced pluripotent stem cells and Kinetic Image Cytometry1R43AG062012-01 | MCDONOUGH, PATRICK M | VALA SCIENCES, INC., CA | $301,078 | ZRG1 |
| 2018 | Evaluation of oral oleocanthal to prevent and/or treat Alzheimer’s disease and related dementias1R43AG061952-01 | CARDELLI, JAMES | OLEOLIVE, INC., LA | $269,634 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.